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A B S T R A C T
Purpose
Hepatocellular carcinoma (HCC) is a common and deadly malignancy with few systemic
therapy options. The RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-
related kinase (ERK) pathway is activated in approximately 50% to 60% of HCCs and
represents a potential target for therapy. Selumetinib is an orally available inhibitor of MEK
tyrosine kinase activity.
Patients and Methods
Patients with locally advanced or metastatic HCC who had not been treated with prior systemic
therapy were enrolled on to the study. Patients were treated with selumetinib at its recommended
phase II dose of 100 mg twice per day continuously. Cycle length was 21 days. Imaging was
performed every two cycles. Biopsies were obtained at baseline and at steady-state in a subset of
patients, and pharmacokinetic (PK) analysis was performed on all patients.
Results
Nineteen patients were enrolled, 17 of whom were evaluable for response. Most (82%) had
Child-Pugh A cirrhosis. Toxicity was in line with other studies of selumetinib in noncirrhotic
patients. PK parameters were also comparable to those in noncirrhotic patients. No radiographic
response was observed in this group, and the study was stopped at the interim analysis. Of 11
patients with elevated -fetoprotein, three (27%) had decreases of 50% or more. Median time to
progression was 8 weeks. Inhibition of ERK phosphorylation was demonstrated by West-
ern blotting.
Conclusion
In this study of selumetinib for patients with HCC, no radiographic responses were seen and time
to progression was short, which suggests minimal single-agent activity despite evidence of
suppression of target activation.
J Clin Oncol 29:2350-2356. © 2011 by American Society of Clinical Oncology
INTRODUCTION
Hepatocellular carcinoma is one of the most com-
mon cancer killers worldwide. Treatment of locally
advanced (unresectable) and metastatic HCC is gen-
erally palliative in nature. Sorafenib is currently con-
sidered the therapy of choice for patients with
advanced HCC on the basis of a randomized trial in
which median overall survival (OS) was improved
from 7.9 months for placebo-treated patients to 10.7
months with sorafenib.1 Although this result is
promising, it is still the case that agents targeting new
mechanisms are an urgent priority for patients
with HCC.
The RAF/mitogen-activated protein kinase ki-
nase (MEK)/extracellular signal-related kinase
(ERK) signaling pathway plays a central role in the
regulation of many cellular processes, including
proliferation, survival, differentiation, apoptosis,
motility, and metabolism.2 Activated RAS triggers
the phosphorylation and activation of RAF ki-
nase, which then phosphorylates MEK1 and
MEK2 on two serine residues.2 Activated MEK
phosphorylates its only known substrates, ERK1
and ERK2. Phosphorylated ERK dimerizes and
translocates to the nucleus,3 where it is involved in
several important cellular functions, including
cell proliferation.
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RAS and RAF mutations are relatively uncommon in HCC,4-6
but there is evidence that, despite this, the RAF/MEK/ERK pathway
may have significance in the progression of HCC. Activation of this
pathway has been demonstrated in 50% to 100% of human HCCs.7-9
This may be in large part due to autocrine/paracrine signaling through
receptor tyrosine kinases, such as epidermal growth factor receptor,
the insulin-like growth factor receptor, or c-MET.10 Additionally, it
was recently noted that HCCs appear to have decreased expression of
inhibitors of the RAS pathway, possibly via methylation of the pro-
moter of the RASSF1A and/or NORE1A genes.11,12 MEK/ERK inhibi-
tion has been studied in HCC cell lines and xenografts with mixed
results. A preclinical study by Klein et al13 utilized several means of
inhibition of the MEK/ERK pathway and demonstrated decreased
proliferation and increased apoptosis in several HCC cell lines. Huynh
et al14 utilized selumetinib against HCC cell lines and again demon-
strated activity in vitro and in xenograft models in more than one
HCC cell line. This group noted decreased activity in one cell line that
did not express significant phospho-MEK.
Selumetinib (AZD6244, ARRY-142886) is a potent, selective,
orally available, and non-ATP–competitive small-molecule inhibitor
of the mitogen-activated protein (MAP) kinase kinase, MEK1/2.16
The recommended phase II dose of selumetinib has previously been
established as 100 mg twice per day orally.17 To our knowledge, this
study represented the first trial of an inhibitor of MEK in patients with
HCC. Because the metabolism of selumetinib is also primarily hepatic,
the study also represented an opportunity to investigate the pharma-
cokinetics (PKs) and safety profile of selumetinib in a population of
patients who have underlying liver disease.
PATIENTS AND METHODS
Patient Selection
This study was an open-label, single-arm, phase II clinical trial evaluating
the efficacy of selumetinib in advanced or metastatic HCC. The study was
performed by the Southeastern Phase II Consortium and the Ohio State
University Phase II Consortium. The human participants committees at each
participating center approved this study, and all patients provided written
informed consent before participation. All trial procedures were conducted in
accordance with the principles established by the Helsinki Declaration.
Patients enrolled on this study had either histologically proven or
-fetoprotein (AFP  1,000 ng/dL) –confirmed HCC. They could not be
considered candidates for potentially curative therapies. Prior regional
therapy or ablative therapy was allowed, but prior systemic therapy (in-
cluding sorafenib) was not. History of liver transplantation was exclusion-
ary (CONSORT, Fig 1).
Eastern Cooperative Oncology Group (ECOG) performance status  1
was required in addition to the following laboratory criteria: leukocytes greater
than 3,000/L, absolute neutrophil count greater than 1,500/L, platelets
greater than 75,000/L, total bilirubin less than two times the upper limit of
normal (ULN), AST/ALT less than five times institutional ULN, creatinine less
than 1.5 mg/dL (or creatinine clearance greater than 60 mL/min), and INR less
than 1.4.
If cirrhosis was present, the patient had to meet criteria for Child-Pugh
class A or B. If Child-Pugh B cirrhosis was present, the patient could not have
significant encephalopathy or ascites that required ongoing paracentesis, and
the patient had to meet the stated laboratory criteria.
Treatment
Selumetinib was formulated as a mix and drink preparation by using
captisol as the diluent. Dosing was 100 mg orally twice per day to patients who
had fasted for a minimum of 2 hours before dosing. Days 1 through 3 of the
study constituted the initial PK analysis; the patient took a single morning dose
of 100 mg selumetinib followed by PK sampling. After the 48-hour PK sample,
patients began twice-daily therapy continuously. A cycle of therapy was 21
days of therapy.
Dose modifications were planned for any grade 3 or 4 toxicities. Up to
two dose reductions were allowed; the first was a reduction to 50 mg twice per
day, and the second was a reduction to 50 mg once daily. Rash was managed
with interruption of therapy for intolerable grade 2 or greater severity followed
by dose reduction after resolution to grade 1 or tolerable grade 2.
PK sampling was performed for the first 15 patients on days 1 through 3
(single-dose PK) and days 15 to 17. Tumor biopsies were performed before day
1 with a 14-gauge to 20-gauge needle and up to four passes. Biopsies were
immediately frozen in liquid nitrogen and were not used for diagnostic pur-
poses. Paired tumor biopsies were obtained in the first five patients; subse-
quently, funding issues required us to amend the protocol to obtain only a
baseline tumor biopsy. Analyses presented are based on the paired biopsy
samples. Imaging for tumor response was performed after every two cycles.
Tumor Biopsy and Western Blot Analysis
Patients who consented to an optional biopsy had paired tumor biopsies
performed before treatment and during treatment with selumetinib 100 mg
orally twice per day on day 7, approximately 2 hours after selumetinib dose
(presumed to be at steady-state). Specimens were snap frozen in liquid nitro-
gen and stored at 80°C until they were additional processed. Weighted
tumor samples were mixed with the appropriate amount of the T-PER tissue
protein extraction reagent (Thermo Scientific, catalog No. 78,510; Rockford,
IL) containing protease inhibitor cocktail, 2 mmol/L phenylmethyl sulfonyl
fluoride, 2 mmol/L Na3VO4, and 6.4 mg/mL p-nitrophenlyphosphate. Sam-
ples were homogenized with the polymerase chain reaction tissue homogeniz-
ing kit (Fisher Scientific, Rockford, IL). The homogenate was centrifuged
at 13,000  g for 30 minutes at 4°C, the supernatant was collected, and the
protein concentration was determined by the Bradford assay. Proteins
were separated by sodium dodecyl sulfate –polyacrylamide gel electropho-
resis and were transferred to nitrocellulose membranes, which were then
blotted with phospho-p44/42 map kinase (p-ERK; Thr202/Tyr204; 9101;
Cell Signaling, Danvers, MA), p44/42 MAP kinase (9102; Cell Signaling),
phospho-MEK1/2 (Ser 217/221; 9121; Cell Signaling), MEK1/2 (9122; Cell
Signaling), phospho-p38 MAPK (Thr180/Tyr182; 12F8; 4631, Cell Signal-
ing), p38 MAP kinase (9212, Cell Signaling), phospho-Akt (Ser473; 9271;
Cell Signaling), Akt1/2 (N-19; SC-1619, Santa Cruz Biotechnology, Santa
Cruz, CA), phospho-STAT3 (Tyr 705; 9131L; Cell Signaling), STAT3 (F-2;
Sc-8019; Santa Cruz Biotechnology, Santa Cruz, CA), GAPDH (MMS-
580S; Covance, Princeton, NJ).
Assessed for eligibility 
(N = 24)
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(n = 19)
(n = 17)
Fig 1. CONSORT diagram.
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PK Analysis
Blood samples for determination of selumetinib and N-desmethyl selu-
metinib were taken on day 1 and day 15. The PK analyses were performed at
Clinical Pharmacology and DMPK, Alderley Park, AstraZeneca, United King-
dom. The PK variables for the patients with comprehensive PK sampling were
estimated by noncompartmental analysis by using WINNonlin (version 5.2,
Scientific Consultant, Apex, NC). The actual sampling time, as opposed to the
protocol-scheduled time, was used in the derivation of PK parameters.
The following parameter estimates were estimated for selumetinib from
the observed concentration-time profiles: maximum plasma concentration
(Cmax), the Cmax at steady-state (Css max), the time of maximum concentration
(tmax), and the tmax at steady-state (tss max). Parameters were determined by
inspection of the concentration-time profiles.
The apparent clearance (CL/F after the single dose and CLss/F after
multiple dosing) were determined from the ratio of dose to area under the
concentration curve (AUC) or dose to AUCss. Apparent volume of distribu-
tion (Vz/F) after oral dosing was calculated by dividing the dose by the product
of z  AUC. The estimated volume of distribution at steady-state after oral
dosing (Vss/F) was determined from the mean residence time (MRT)  CL/F.
The accumulation ratio (RAC) was calculated as the ratio of the AUCss
and AUC(0-12) on day 1. The AUC(0-12) was determined for N-desmethyl
selumetinib on days 1 and 15 to enable the calculation of the metabolite-to-
parent percentage on days 1 and 15 (N-desmethyl selumetinib AUC(0-12) 
selumetinib AUC(0-12)  100). The time dependency (Tc or linearity factor) of
the pharmacokinetics on multiple dosing was assessed by the calculation of the
ratio of AUCss to AUC on day 1.
Statistical Methods
The primary end point was the objective response rate. Secondary end
points included the time to event functions of progression, progression-free
survival (PFS), and overall survival (OS). For sample size calculation,
an optimal two-stage design18 was used. The information used in the
calculations of this design were the values of P0  .03, P1  .15,  .1, and
power  90%.
In the first stage, 19 patients were entered, with the assumption that at
least 17 would be eligible. If there was at least one response among these 17
eligible patients, an additional 25 patients would have been entered for the
second stage, of whom 22 would be assumed to be eligible. Thus, a total of 44
patients could have been enrolled on the study. The probability of early
stopping was 0.60 if the true response rate was 0.03, and it was 0.06 if the true
response rate was 0.15. Moreover, the overall probability of rejecting the
treatment was 0.90 if the true response rate was 0.03, and it was 0.10 if the true
response rate was 0.15.
Statistical Analysis
The Kaplan-Meier (or product-limit) method was used to estimate all
time-to-event functions. Time to disease progression (TTP) has been defined
as the time from the start of treatment to disease progression. Deaths occurring
in the absence of proven disease progression were censored. PFS has been
defined as time from the start of treatment to disease progression or death as a
result of any cause. OS has been defined as time from the start of treatment to
deathasaresultofanycause.Exact95%CIswerecalculatedforeachproportionof
interest. These proportions have been reported as percentages. Statistical analyses
wereperformedwithSASstatisticalsoftware(version9.2,SASInstitute,Cary,NC).
PK analysis was performed with software noted in the Methods section, and
parameter estimates were summarized with descriptive statistics.
RESULTS
Patient Demographics and Clinical Outcomes
Nineteen patients were enrolled between November 8, 2007, and



































































Fig 2. Western blot derived from frozen biopsy samples taken at baseline and
day 8 ( 3 days) of selumetinib therapy demonstrating baseline and post-
treatment phosphorylation of ERK1/2, MEK1/2, p38, Akt, and STAT3. Samples
demonstrated baseline activation of ERK1/2 in all samples tested and inhibition of
ERK phosphorylation after selumetinib therapy but, as expected, no changes in
MEK phosphorylation status.
Table 1. Patient Demographic and Clinical Characteristics
Characteristic





Male sex 13 76
ECOG PS
0: fully active 5 31
1: restricted 9 56
2: ambulatory 2 13
Child-Pugh
A/B/not reported† 14 21
HCV/HBV/both 13 11
No viral infection 2
PV thrombus 6 35




Abbreviations: ECOG, Eastern Cooperative Oncology Group; PS, perfor-
mance status; HCV, hepatitis C virus; HBV, hepatitis B virus; PV, portal vein.
n  1 missing.
†Includes patients with no cirrhosis clinically.
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baseline are listed in Table 1. All 19 patients were considered evaluable
for toxicity. Of the 19, two patients failed to complete a full cycle of
therapy, one because of elevated serum transaminases that did not
resolve after holding study medication (which was felt to be secondary
to rapid disease progression) and the second as a result of voluntary
withdrawal from protocol after 1 week of therapy without any grade 3
toxicities. As such, 17 patients were considered evaluable for the pri-
mary end point of radiographic response. Among these 17 patients,
therewasnopartial responseorcompleteresponse; therefore, enrollment
tothetrialwashaltedat the interimanalysis.Withamediantimeonstudy
of 6 weeks (range, 1 to 33 weeks), the best response rate of stable disease
(SD) was six (35%) of 17 patients (exact 95% CI, 14% to 62%).
Eleven (65%) of 17 evaluable patients (exact 95% CI, 38% to
86%) had elevated AFP at baseline ( 200 ng/dL). Among these
patients, AFP decreased by 50% or more in three patients (27%; exact
95% CI, 6% to 61%). One patient’s AFP decreased significantly after 3
weeks of therapy from a peak of 79,725 ng/dL to 700 ng/dL. That
patient went on to demonstrate radiographic progression at the sub-
sequent (second) magnetic resonance imaging evaluation. After re-
moval from protocol, the patient was started on sorafenib and
demonstrated a relatively dramatic partial response at the first evalu-
ation roughly 12 weeks later. This patient is represented as patient five
(far right) in Figure 2, in which it can be seen that the patient had high
levels of phospho-ERK and MEK at baseline, with significant inhibi-
tion of phospho-ERK by selumetinib.
Of the 17 evaluable patients, 14 patients died, two patients expe-
rienced progression, and one patient neither experienced progression
nor died. The median PFS was 1.4 months (95% CI, 1.2 to 2.5
months). Median TTP was essentially the same. Median OS was 4.2
months (95% CI, 1.9 to 6.0). Follow-up times for the three surviving
patients were 3.4, 12.5, and 15.2 months.
Toxicity
Toxicity was no greater than expected from prior studies of
selumetinib. The main toxicities were low-grade but persistent nausea
and maculopapular rash. The most commonly observed grade 3 and 4
toxicities possibly related to treatment are listed in Table 2. No ocular
toxicity was noted, although ocular acuity testing was not required;
hence, minor ocular toxicities may have been underreported. There
were no significant cardiac events, although, again, repeated testing of
ejection fraction was not required by the protocol.
PKs
The PK parameters are listed in Tables 3 and 4. Absorption was
rapid, with median tmax and tmax ss of 1.5 hours and 1 hour, respec-
tively; Cmax ss was achieved in the majority of individuals (12 of 13)
between 0.5 and 2 hours after dosing. The variability in the peak
plasma concentration was moderate to high. After the peak, plasma
concentrations declined (Fig 3) with a mean terminal elimination
half-life (t1/2) of 10 hours and a range of 6 to 16 hours. The mean
apparent oral plasma clearance (CLss/F) was 36L/h (range, 16 to 82
L/h). The N-desmethyl metabolite was approximately 5% of the par-
ent AUC on day 1 and AUCss on day 15 (range, 2% to 11%). The mean
accumulation for selumetinib to steady-state was approximately 1.5-
fold and ranged from 0.2-fold to 4.3-fold for AUCss.
There was no apparent relationship between exposure and liver
function, as measured by albumin and bilirubin (Fig 4), although the
number of patients with levels consistent with Child-Pugh scoring of  6
was low.ThreepatientshadChild-PughclassB liverdisease;PKdatawere
available for two of these, and one of these patients had the highest ob-
served exposure in the study population. The exposure in patients in this
study was generally in a similar range to that observed in patients with
other tumor types in the selumetinib clinical program (data not shown).
MEK Inhibition in Tissue Samples
To determine the effects of selumetinib on the activities of MEK
and other signal transduction pathways in patients with locally ad-
vanced or metastatic HCC, pre- and post-tumor biopsies were ana-
lyzed for the phosphorylation levels of ERK1/2, MEK1/2, p38, Akt,
and STAT3. Figure 2 shows that four of five patients (patients 1, 2, 4,
and 5) achieved significant inhibition of phopho-ERK1/2 levels in
tumors. As would be expected, selumetinib treatment resulted in little







Alkaline phosphatase 1 5
Bilirubin for hyperbilirubinemia 1 5
Fatigue (ie, asthenia, lethargy, malaise) 1 5
Glucose, serum high (ie, hyperglycemia) 1 5
Potassium, serum low (ie, hypokalemia) 1 5
Sodium, serum low (ie, hyponatremia) 1 5
Abbreviation: CDUS, clinical data update system.
Table 3. Pharmacokinetic Parameters After Selumetinib Single Oral 100-mg Dose to Steady-State


















No. evaluated 14 14 14 13 13 13 13 12
Mean 734 3,299 5,219 29 415 10 5.7
SD 795 2,690 3,697 20 309 3 2.4
Min 0.5 123 777 1,300 7 114 6 1.7
Max 4 3,140 10,384 14,251 77 1,126 16 10.8
Abbreviations: tmax, time of maximum concentration; Cmax, maximum plasma concentration; AUC0-12, area under the concentration curve from 0 to 12 hours; AUC,
area under the concentration curve; CL/F, apparent clearance; Vz/F, apparent volume of distribution; t1/2, half life; SD, standard deviation; Min, minimum; Max, maximum.
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effect on the phospho-MEK1/2 levels in four of the five patients
(because this is mediated by RAF upstream).
To determine the selectivity of selumetinib we also analyzed its
effects on the phosphorylation of another MAP kinase protein, p38.
Figure 2 shows that treatment with selumetinib resulted in a decrease
of phospho-p38 in patient 1, an increase in patients 2 and 3, and little
effect on patients 4 and 5. These results suggest that the inhibition of
MEK kinase in these patients is complex and has different conse-
quences depending on the individual patient tumor.
We next evaluated the effect of selumetinib on other oncogenic
pathways, such as Akt and STAT3. Whereas the effects of selumetinib
on the phospho-STAT3 levels were subtle, the effects on phospho-Akt
were pronounced in some tumors (Fig 2). Furthermore, the results
show that treatment with selumetinib resulted in mixed effects on the
phosphorylation levels of Akt.
DISCUSSION
To our knowledge, this study represented the first study of an inhibitor
of MEK in patients with HCC. The preclinical rationale for the use of
this class in this population was strong. However, in the patient pop-
ulation studied, monotherapy activity of selumetinib was minimal
despite treatment with the agent at full dose. Tolerability of the drug
was similar in this population to that reported in other popula-
tions17,19 and cannot be considered the principal reason for lack of
efficacy in this trial. Our study utilized RECIST (Response Evaluation
Criteria in Solid Tumors) to evaluate response. RECIST has been
criticized in HCC because of inherent difficulty in imaging HCCs and
because devascularization rather than tumor shrinkage may be a hall-
mark of response in HCC. Recently, a modified RECIST has been
proposed,20 but it is not yet considered standard for clinical trials of
systemic agents.
Interestingly, Abou-Alfa et al15 described improved prognosis in
HCC patients treated with sorafenib whose tumors demonstrated
high nuclear phospho-ERK levels by immunohistochemistry on
paraffin-embedded samples. This analysis was difficult to interpret,
however, given lack of placebo-treated patients in the study. As such,
the question remains about whether ERK activation is prognostic or
predictive of response to sorafenib activity. Our results suggest that
this finding was not likely due to the effects of sorafenib on the
Table 4. Pharmacokinetic Parameters After Selumetinib Oral 100-mg Oral Twice-Daily Dose to Steady-State
















No. evaluated 13 13 13 13 13 12 11 12
Mean 647 3,473 36 328 1.5 0.9 4.9
SD 401 1,613 19 289 1.1 0.5 1.7
Min 0.5 135 1,220 16 88 0.2 0.2 2.2
Max 4 1600 6175 82 1023 4.3 1.9 7.8
Abbreviations: tmax ss, time of maximum concentration at steady-state; Cmax ss, maximum plasma concentration at steady-state; AUCss, area under the
concentration curve at steady-state; CLss/F, apparent clearance at steady-state; Vss/F, estimated volume of distribution at steady-state; RAC, accumulation ratio; Tc,
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Fig 3. Mean and standard deviation selumetinib and N-desmethyl selumetinib
plasma concentrations after single and twice daily dosing of selumetinib to


























10 2 3 4 5 6
Fig 4. Selumetinib area under the concentration curve (AUC) as a function of
serum albumin on days 1 and 15 demonstrates no trend toward increased or
decreased exposure on the basis of albumin (as a surrogate for severity of liver
disease). AUCss, AUC at steady-state.
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RAF/MEK/ERK pathway, but rather they suggest the possibility that
phospho-ERK expression represented a favorable prognostic factor
(rather than a predictive one, as suggested in the discussion of the
study by Abou-Alfa et al15). Little other data on this topic exist in the
literature. Of note, we recently identified increasing degrees of
phospho-ERK expression as a positive prognostic factor in rectal can-
cer (O’Neil et al, manuscript in preparation). The data from this study
along with other studies of other vascular endothelial growth factor
pathway antagonists suggest vascular endothelial growth factor recep-
tor inhibition as the main activity of sorafenib in HCC.21 Additionally,
our data suggest that phospho-ERK expression may not be an ade-
quate selection factor for therapy with MEK inhibitors. Studies in
several tumor types, particularly melanoma, suggest that cancers har-
boring BRAF mutations may be particularly sensitive to MEK inhibi-
tion.22 Some in vivo experiments have demonstrated that tumors with
KRAS mutations may also be sensitive,23 although others have refuted
this.24 Interestingly, in a recently completed trial of selumetinib in
cholangiocarcinoma, responding patients harbored neither KRAS nor
BRAF mutations,25 so true predictors of response remain elusive in
many, if not most, disease states.
In a subset of patients, we demonstrated that MEK phosphor-
ylation was present in all patient cases sampled and that, at day 8 of
therapy, MEK phosphorylation was in fact inhibited in the tumor
by the studied dose of selumetinib in four of five patients. This
suggests that inactivity of the compound was not explained by lack
of target inhibition. Our studies of downstream effects of MEK
inhibition on Akt, STAT, and p38 showed mixed effects of MEK
inhibition, and our conclusions in this regard are quite limited
because of small numbers.
Another potential explanation for lack of activity of this com-
pound in HCC could relate to differential exposure in the cirrhotic
population compared with a noncirrhotic one. Fifteen of 19 pa-
tients in our study had cirrhosis, and the vast majority were Child-
Pugh class A. PK analysis of our population is again somewhat
limited by numbers, but there was no suggestion of a significant
difference in PK parameters between patients in our study and
those in prior studies of AZ6244 (Maria Learoyd, Astra Zeneca,
personal communication).
In summary, this study represented, to our knowledge, the first
study of an inhibitor of MEK in HCC. The study was terminated early
because of a lack of radiographic responses and short PFS, which both
reflect the lack of adequate antitumor activity with selumetinib
as monotherapy.
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